Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Reiterated by HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 198.73% from the stock’s previous close.

A number of other brokerages also recently issued reports on DAWN. Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, May 7th. JPMorgan Chase & Co. upped their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday, April 22nd. Needham & Company LLC restated a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday. The Goldman Sachs Group decreased their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Finally, Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $13.39 on Thursday. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $18.07. The company’s 50-day moving average is $14.72 and its 200 day moving average is $14.71. The stock has a market capitalization of $1.17 billion, a P/E ratio of -5.33 and a beta of -1.53.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.05). Research analysts anticipate that Day One Biopharmaceuticals will post -2.69 earnings per share for the current year.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,267 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $36,453.36. Following the completion of the transaction, the insider now directly owns 1,171,081 shares in the company, valued at $18,830,982.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Samuel C. Blackman sold 2,267 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $36,453.36. Following the transaction, the insider now owns 1,171,081 shares of the company’s stock, valued at approximately $18,830,982.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $16.02, for a total transaction of $160,200.00. Following the completion of the transaction, the insider now directly owns 1,174,662 shares in the company, valued at $18,818,085.24. The disclosure for this sale can be found here. Insiders have sold a total of 185,534 shares of company stock valued at $3,236,030 over the last quarter. 8.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quest Partners LLC acquired a new position in Day One Biopharmaceuticals during the 4th quarter valued at approximately $29,000. Quintet Private Bank Europe S.A. raised its stake in shares of Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Day One Biopharmaceuticals by 35.7% during the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after purchasing an additional 2,268 shares during the period. Exchange Traded Concepts LLC increased its holdings in Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after buying an additional 2,554 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Day One Biopharmaceuticals by 352.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock valued at $147,000 after acquiring an additional 7,841 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.